GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Enterprise Value

AIM ImmunoTech (STU:HXB2) Enterprise Value : €8.06 Mil (As of May. 12, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AIM ImmunoTech's Enterprise Value is €8.06 Mil. AIM ImmunoTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-29.03 Mil. Therefore, AIM ImmunoTech's EV-to-EBIT ratio for today is -0.28.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, AIM ImmunoTech's Enterprise Value is €8.06 Mil. AIM ImmunoTech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-28.81 Mil. Therefore, AIM ImmunoTech's EV-to-EBITDA ratio for today is -0.28.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, AIM ImmunoTech's Enterprise Value is €8.06 Mil. AIM ImmunoTech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.19 Mil. Therefore, AIM ImmunoTech's EV-to-Revenue ratio for today is 42.89.


AIM ImmunoTech Enterprise Value Historical Data

The historical data trend for AIM ImmunoTech's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Enterprise Value Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 34.49 -1.92 -17.32 9.82

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.32 -8.78 3.49 0.92 9.82

Competitive Comparison of AIM ImmunoTech's Enterprise Value

For the Biotechnology subindustry, AIM ImmunoTech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Enterprise Value distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Enterprise Value falls into.



AIM ImmunoTech Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

AIM ImmunoTech's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

AIM ImmunoTech's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (STU:HXB2) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

AIM ImmunoTech's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8.063/-29.028
=-0.28

AIM ImmunoTech's current Enterprise Value is €8.06 Mil.
AIM ImmunoTech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-29.03 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

AIM ImmunoTech's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=8.063/-28.806
=-0.28

AIM ImmunoTech's current Enterprise Value is €8.06 Mil.
AIM ImmunoTech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.81 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

AIM ImmunoTech's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.063/0.188
=42.89

AIM ImmunoTech's current Enterprise Value is €8.06 Mil.
AIM ImmunoTech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech Enterprise Value Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines